20.10.2007 00:09:00
|
Accelrys Announces the Appointment of Rohit Shyam as Vice President, Corporate Development and Strategy
Accelrys, Inc. (NASDAQ:ACCL) a leading provider of scientific business
intelligence solutions announced today the appointment of Rohit Shyam as
Vice President, Corporate Development and Strategy.
Most recently, Mr. Shyam served as Partner, Senior Strategy Expert, and
Solution Director for Computer Sciences Corporation in the Global Health
Solutions sector. In his role at Computer Sciences Corporation Mr. Shyam
developed and delivered solutions that addressed industry trends and
challenges in pharmaceuticals, biotech, agri-biotech and medical devices.
Prior to joining Computer Sciences Corporation, Mr. Shyam was a
Principal at IBM, where he helped launch its life sciences practice. He
also led strategic consulting initiatives as a Principal at Booz Allen
Hamilton and has had success as a start-up company entrepreneur.
Commenting on Mr. Shyam’s appointment, Mark J.
Emkjer, Accelrys’ President and Chief
Executive Officer, said: "Accelrys is at the
point where we need someone to focus full time on corporate development,
mergers and acquisitions and strategy. Rohit’s
background and expertise in the life science market and understanding of
the applications of business intelligence software make him an excellent
choice for this role.”
Mr. Shyam holds a B.S. in Computer Engineering from Lehigh University
and an M.B.A. from The Kellogg School of Management at Northwestern
University.
About Accelrys, Inc.
Accelrys develops and commercializes scientific business intelligence
software for the integration, mining, analysis, modeling and simulation,
management and interactive reporting of scientific data. Our solutions
are used by biologists, chemists, materials scientists, and information
technology professionals for product design as well as drug discovery
and development. Our technology and services are designed to meet the
needs of today’s leading research and
development organizations including leading commercial, government and
academic organizations. Many of the largest pharmaceutical,
biotechnology, chemical, and petroleum companies worldwide use our
solutions. Accelrys is headquartered in San Diego, California. For more
information about Accelrys, visit its website at http://www.accelrys.com/ Forward-Looking Statements
This press release contains forward-looking statements. Such statements,
including statements relating to the potential mergers, acquisitions and
the Company’s scientific business intelligence
strategy, and the implementation thereof, are subject to risks and
uncertainties including, but not limited to, the risks that the such
mergers, acquisitions or Company’s strategy
will not be successful, and other risks and uncertainties described in
documents Accelrys has filed with the Securities and Exchange
Commission, including its most recent report on Form 10-K and any
subsequent interim filings. All forward-looking statements in this
document are qualified entirely by the cautionary statements included in
this document and such filings. These risks and uncertainties could
cause actual results to differ materially from results expressed or
implied by forward-looking statements contained in this document. These
forward-looking statements speak only as of the date of this document.
Accelrys disclaims any intent or obligation to publicly update or revise
any forward-looking statements contained herein to reflect any change in
its expectations with regard thereto or any change in events, conditions
or circumstances on which any such statement is based.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Accelrys Inc Cash Settlement At USD 12.50 A Shmehr Nachrichten
Keine Nachrichten verfügbar. |